Curis Hedgehog and Beyond --plus multi-targeting cancer inhibitors

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

http://www.clinicaltrials.gov/ct2/show/NCT01096732?term=GDC-0449
Purpose
This clinical trial is looking at the effect of a new drug called GDC-0449 in patients with cancer of the pancreas. Laboratory studies have shown that this drug blocks a process in pancreatic cells thought to be involved in cancer development and spread. This process is called the 'Hedgehog signalling pathway'. As yet, it is unclear whether blocking hedgehog signalling will ...

Chronic Myeloid Leukemia (CML) Phase I
http://clinicaltrials.gov/ct2/show/NCT00953758?term=PF-04449913
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies. Part two of the study will examine the effect of this inhibitor in combination with dasatinib.

Study Start Date: January 2010
Estimated Study Completion Date: April 2013


http://clinicaltrials.gov/ct2/results?term=PF-04449913

Extensive-Stage Small Cell Lung Cancer Phase I
http://clinicaltrials.gov/ct2/show/NCT00927875?term=BMS-83392
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).

Study Start Date: December 2009
Estimated Study Completion Date: July 2011

Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas Phase I
http://clinicaltrials.gov/ct2/show/NCT00909402?term=BMS-833923
The purpose of this study is to determine the maximum tolerated dose ...